

Listing of the claims:

21. (previously amended) A method of treating sexual dysfunction which comprises administering by inhalation an effective amount of an inhibitor of cGMP PDE 5 in an atomisable composition or a finely divided particulate form to a subject in need of such treatment, wherein said inhibitor is selected from the group consisting of 5-[2-ethoxy-5-(4-methylpiperazinyl-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)quinazoline, 4-phenyl-methylamino-6-chloro-2-(3-pyridyl)-quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methane-sulfonylamidophenyl)-1,5-dihdropyrazolo[3,4-d]pyrimidin-4-one and 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4pyridyl)-pyrazolo[3,4-d]pyrimidin-4-one.
25. (previously added) A method according to claim 21, in which said atomisable composition is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.
26. (previously added) A method according to claim 21, in which said inhibitor in finely divided particulate form is inhaled together with a particulate carrier.
27. (previously added) A medicament comprising 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)-quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl)quinazoline, or 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihdropyrazolo[3,4-d]pyrimidin-4-one in an atomisable composition or a finely divided particulate form.
28. (previously added) A medicament according to claim 27, in which the atomisable composition is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.
29. (previously added) A medicament according to claim 27, in which said inhibitor in finely divided particulate form is inhaled together with a particulate carrier.
30. (previously added) A method of treating sexual dysfunction which comprises administering by inhalation an effective amount of 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one in an atomisable composition or a finely divided particulate form to a subject in need of such treatment.

31. (previously added) A medicament comprising 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]-pyrimidin-7-one in an atomisable composition or a finely divided particulate form.

32. (previously added) A medicament according to Claim 31, in which the atomisable composition is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.

33. (previously added) A medicament according to Claim 31, in which said inhibitor in finely divided particulate form is inhaled together with a particulate carrier. --